KRAS and cancer: Another study analyzing calcium channel inhibitors on cancer cell proliferation showed that the L-type calcium channel blocker fendiline, which belongs to the non-dihydropyridine class, inhibits proliferation of PDAC cells that carry activating mutations in K-Ras (MiaPaCa2, MOH, HPAC and MPanc96) by affecting Ras localization and downstream signaling, while cells that do not carry a Ras mutation (BxPC3) are not affected [77].